Fawzy A, Hendry A, Cook E, Gonzalez F
Urologic Institute of New Orleans and Department of Nephrology, Louisiana State University Medical Center, 70056, USA.
Int J Urol. 1999 Jul;6(7):346-54. doi: 10.1046/j.1442-2042.1999.00071.x.
The alpha1-adrenoceptor antagonist doxazosin has proved successful in treating patients with concurrent benign prostatic hyperplasia (BPH) and hypertension in short-term studies. However, both conditions are chronic and may worsen over time. The aim of this study was, therefore, to examine the tolerability and efficacy of doxazosin in the long-term treatment of concurrent BPH and hypertension.
This study was a longitudinal extension of earlier double-blind trials. Patients were enrolled into the study on a rolling basis. From a total of 178 BPH patients with hypertension enrolled into the study, 28 had reached 48 months of open-label treatment with doxazosin at the time of the final data cutoff.
Treatment with doxazosin resulted in sustained benefits for BPH patients over the whole study period, with significant improvements in the severity (12.2%, P < 0.001) and bothersomeness (13.2%, P < 0.001) of BPH symptoms, and in the maximum urinary flow rate (26.6%, P < 0.05) from baseline to the end of the 4-year period. There was also a significant and sustained reduction in diastolic blood pressure. The efficacy of doxazosin treatment for both BPH and hypertension was maintained over the 4-year period, despite the tendency of these conditions to worsen with time. Comparison of adverse events in patients with long- and short-term hypertension and BPH demonstrates that the safety of doxazosin is not altered during long-term therapy.
This study demonstrates that doxazosin appears to be well tolerated and efficacious in the long-term management of concurrent BPH and hypertension.
在短期研究中，α1肾上腺素能受体拮抗剂多沙唑嗪已被证明在治疗同时患有良性前列腺增生（BPH）和高血压的患者方面取得了成功。然而，这两种疾病都是慢性的，且可能随时间恶化。因此，本研究的目的是探讨多沙唑嗪在长期治疗同时患有BPH和高血压患者中的耐受性和疗效。
本研究是早期双盲试验的纵向延伸。患者以滚动方式纳入研究。在最终数据截止时，从总共178名纳入研究的患有高血压的BPH患者中，有28名已接受多沙唑嗪开放标签治疗达48个月。
在整个研究期间，多沙唑嗪治疗使BPH患者持续受益，BPH症状的严重程度（12.2%，P < 0.001）和困扰程度（13.2%，P < 0.001）以及最大尿流率从基线到4年期末均有显著改善（26.6%，P < 0.05）。舒张压也有显著且持续的降低。尽管这些疾病有随时间恶化的趋势，但多沙唑嗪治疗BPH和高血压的疗效在4年期间得以维持。对长期和短期高血压及BPH患者不良事件的比较表明，多沙唑嗪在长期治疗期间的安全性未改变。
本研究表明，多沙唑嗪在长期管理同时患有BPH和高血压患者方面似乎耐受性良好且有效。
